Delivery Order SPE2DB20D2014-SPE2DB25FA45N

Award Date 11/27/24
Potential Completion Date 12/19/24
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,846.97 firm-fixed-price contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has an ultimate completion date of July 15, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product, with a ceiling value of $13,846.97 and a period of performance through May 13, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $12,960.30 Firm Fixed Price contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has a period of performance through May 30, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,846.97 firm fixed-price contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a medical supply, with a performance period ending on June 11, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,960.30, is a delivery order for VYNDAMAX 61 MG CAPSULE UD 30S, a specialty medication. The contract has a firm fixed-price pricing type and an ultimate completion date of November 14, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has a ceiling value of $41,540.91 and is a firm fixed price delivery order, with a period of performance ending on June 12, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant $999,999,999.00...
This is a $27,693.94 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product, with a period of performance through June 12, 2025. The contract is a firm-fixed-price delivery order, without a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $41,540.91 firm-fixed-price delivery order is for VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has an ultimate completion date of June 17, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This is a firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $13,846.97, is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S. This delivery order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The IDC allows...
This is a $13,846.97 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, with a period of performance ending on July 15, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB25FA45N
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $13,408.24 firm fixed-price contract is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product, with a period of performance through December 19, 2024.

AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

Generated 2/26/25, 9:42 AM